ARCHIVES

ODAC votes 9-6 in favor of Clolar for pediatric acute lymphoblastic leukemia, but votes against Marqibo for non-Hodgkin’s lymphoma.

This article is from The Cancer Letter archive.

Vol. 30 No. 46 | December 10, 2004

Download PDF Visit The Full Archive

Related Articles

Human Genome Consortium Completes “Working Draft”.

June 30, 2000

Samuel Waksal Resigns From ImClone Following Unimpressive ASCO Presentation

May 24, 2002

Kansas City Clinic Settles Medicare Overbilling Claim

June 6, 2014

Francis Collins Nominated For NIH Director Two Days After Final Stem Cell Guidelines Released.

July 10, 2009

OAM Director Jacobs To Leave; Cites “Conflict with Conscience”

July 15, 1994

Bipartisan Deal Eases Some Budget Cuts By Extending Sequestration Through 2023

December 13, 2013